Bioton plans to begin registration of insulin analogues in mid-2018
…insulin and insulin analogues. Bioton also wants to complete the ongoing reorganisation of its structures and processes this year, and to continue its expansion on foreign markets. This should translate into gradual improvement of the company’s financial performance, Mr Neymann said.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)